👵 Ozempic Face: GLP-1 and Aesthetic Surgery
This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients undergoing rapid weight loss from GLP-1 receptor agonists like Ozempic. The authors, plastic surgery residents and a practicing plastic surgeon, present a systematic review of existing literature on these medications within plastic […]
✨ GLP-1s and Post-Weight Loss Plastic Surgery Trends
There is growing evidence—especially in the plastic surgery community—that the recent surge in GLP‑1 medications (like Ozempic, Wegovy, Mounjaro) for weight loss is fueling a wave of “trim & sculpt” surgeries to address excess skin and volume loss. 📈 Trend & Clinical ReviewsThe American Society of Plastic Surgeons and multiple industry blogs report an increase […]
💉 Counterfeit Ozempic: FDA Warns of Unsafe Drug Supply (4/14/2025)
The provided text, originating from the Food and Drug Administration (FDA), serves as a crucial public health warning regarding counterfeit Ozempic (semaglutide) injections found within the U.S. drug supply chain. It details multiple instances where fake versions of the medication were identified and seized, highlighting specific lot and serial numbers to help consumers, pharmacies, and healthcare professionals identify these fraudulent products. The […]
Obesity Treatment Outcomes with Semaglutide or Tirzepatide
This original research article examines the real-world effectiveness of semaglutide and tirzepatide for obesity treatment, focusing on how medication discontinuation impacts weight loss and glycemic control. The retrospective cohort study analyzed electronic health records from a large patient population in Ohio and Florida. It reveals that discontinuation of these pharmacotherapies is common and significantly reduces the average weight reduction and improvement in glycated hemoglobin levels compared to continuous treatment. The findings suggest that maintaining […]
Unpacking the GLP-1 Gold Rush
We ask experts for their views on the GLP-1 market in this exclusive eBook. GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to headline-grabbing agents of a global weight-loss revolution. But the science, strategy, and scale behind these therapies are far more complex than the public narrative suggests. This exclusive eBook, The GLP-1 Gold […]
Your Weight Matters Region
Your Weight Matters Regional is traveling the country, bringing expert-led education and practical guidance to cities near you. These FREE half-day events are designed to meet you wherever you are in your journey—whether you’re just starting to explore your options or want to better understand your health.Each event features a physician, mental health professional and […]
CagriSema: Weight Loss in Overweight or Obese Adults
This document details a Phase 3a, 68-week, multicenter, double-blind, placebo-controlled, and active-controlled clinical trial (REDEFINE 1) investigating the efficacy and safety of cagrilintide–semaglutide (CagriSema) for weight loss in adults who are overweight or obese. The study randomized over 3400 participants into groups receiving the combination therapy, semaglutide alone, cagrilintide alone, or placebo, alongside lifestyle interventions. Results demonstrated significant and clinically relevant body-weight […]
GLP-1 Agonists: Uses, Mechanism, and Side Effects
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these injectable drugs mimic a natural hormone to regulate blood sugar, slow digestion, and increase feelings of fullness, leading to potential weight loss. The source lists various approved GLP-1 agonists and their typical administration frequencies, […]
Orforglipron for Early Type 2 Diabetes Management
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines – Other Posters and Talks
🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”Presenter: Dr. Lloyd L. Tran (CEO)Date & Time: June 20, 2025 – oral session (specific time TBD at conference)Poster:Title: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial […]